Product Description
Zonisamide is a benzisoxazole derivative, chemically unrelated to other antiepileptic drugs, that appears to have multiple mechanisms of action, including inhibition of Na(+) channels and reduction of T-type Ca(2+) currents. It is currently licensed in Europe and the USA for adjunctive treatment of partial seizures in adults, and in Europe as monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23106522/)
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bulgaria | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Netherlands | Norway | Pakistan | Philippines | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: Advanz Pharma
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Epilepsy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016-004954-13 | P3 |
Active, not recruiting |
Epilepsy |
2022-10-05 |
|
| 2016-004951-55 | P3 |
Active, not recruiting |
Epilepsy |
2016-02-18 |